X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (63) 63
index medicus (54) 54
life sciences (41) 41
cancer (38) 38
male (36) 36
female (34) 34
middle aged (34) 34
aged (30) 30
oncology (28) 28
adult (27) 27
chemotherapy (23) 23
gastroenterology & hepatology (19) 19
metastasis (15) 15
aged, 80 and over (14) 14
human health and pathology (13) 13
survival (13) 13
[sdv.can]life sciences [q-bio]/cancer (12) 12
liver cancer (12) 12
tumors (12) 12
cancer therapies (11) 11
care and treatment (11) 11
expression (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
carcinoma (10) 10
clinical trials (10) 10
colorectal cancer (10) 10
patients (10) 10
prognosis (10) 10
retrospective studies (10) 10
surgery (10) 10
hepatocellular carcinoma (9) 9
mutation (9) 9
treatment outcome (9) 9
[ sdv.can ] life sciences [q-bio]/cancer (8) 8
analysis (8) 8
animals (8) 8
biochemistry, molecular biology (8) 8
biomarkers (8) 8
disease-free survival (8) 8
gastroenterology and hepatology (8) 8
irinotecan (8) 8
oxaliplatin (8) 8
radiotherapy (8) 8
cetuximab (7) 7
colorectal neoplasms - drug therapy (7) 7
colorectal-cancer (7) 7
gemcitabine (7) 7
hépatology and gastroenterology (7) 7
liver (7) 7
medical prognosis (7) 7
neoplasm staging (7) 7
rectal cancer (7) 7
research (7) 7
sorafenib (7) 7
therapy (7) 7
[sdv.mhep.heg]life sciences [q-bio]/human health and pathology/hépatology and gastroenterology (6) 6
biochemistry (6) 6
biopsy (6) 6
camptothecin - analogs & derivatives (6) 6
carcinoma, hepatocellular - pathology (6) 6
cell line, tumor (6) 6
colorectal neoplasms - pathology (6) 6
combination (6) 6
deoxycytidine - analogs & derivatives (6) 6
digestive system diseases (6) 6
disease progression (6) 6
drug therapy (6) 6
enteral nutrition (6) 6
gene expression (6) 6
liver - metabolism (6) 6
liver neoplasms - pathology (6) 6
metastases (6) 6
mice (6) 6
pancreatic cancer (6) 6
1st-line treatment (5) 5
[ sdv ] life sciences [q-bio] (5) 5
[sdv.bbm.gtp]life sciences [q-bio]/biochemistry, molecular biology/genomics [q-bio.gn] (5) 5
[sdv]life sciences [q-bio] (5) 5
abridged index medicus (5) 5
adenocarcinoma (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
camptothecin - administration & dosage (5) 5
cancer patients (5) 5
combined modality therapy (5) 5
comparative analysis (5) 5
constitutive androstane receptor (5) 5
enzymology (5) 5
fluorouracil (5) 5
genomics (5) 5
leucovorin (5) 5
liver neoplasms - drug therapy (5) 5
niacinamide - analogs & derivatives (5) 5
pancreatic neoplasms - drug therapy (5) 5
prospective studies (5) 5
proteins (5) 5
proto-oncogene proteins - genetics (5) 5
proto-oncogene proteins p21 (5) 5
radiology, nuclear medicine & medical imaging (5) 5
ras proteins - genetics (5) 5
young adult (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Vilgrain, Valérie and Pereira, Helena and Assenat, Eric and Guiu, Boris and Ilonca, Alina Diana and Ilonca, Alina D and Pageaux, Georges-Philippe and Sibert, Annie and Bouattour, Mohamed and Lebtahi, Rachida and Allaham, Wassim and Barraud, Hélène and Laurent, Valérie and Mathias, Elodie and Bronowicki, Jean-Pierre and Tasu, Jean-Pierre and Perdrisot, Rémy and Silvain, Christine and Gerolami, René and Mundler, Olivier and Seitz, Jean-Francois and Vidal, Vincent and Aubé, Christophe and Oberti, Frédéric and Couturier, Olivier and Brenot-Rossi, Isabelle and Raoul, Jean-Luc and Sarran, Anthony and Costentin, Charlotte and Itti, Emmanuel and Luciani, Alain and Adam, René and Lewin, Maïté and Samuel, Didier and Ronot, Maxime and Dinut, Aurelia and Castera, Laurent and Chatellier, Gilles and Delhom - Christol, Elisabeth and Lonjon, Julie and Abdel-Rehim, Mohamed and Dieudonné, Arnaud and Bazin, Christophe and Chagneau-Derrode, Carine and Borentain, Patrick and Bouvier, Antoine and Vervueren, Laurent and Chalaye, Julia and Kobeiter, Hicham and Edeline, Julien and Garin, Etienne and Rolland, Yan and Archambeaud, Isabelle and Eugene, Thomas and Frampas, Eric and Cassinotto, Christophe and Guyot, Martine and Hiriart, Jean-Baptiste and Lapuyade, Bruno and Vergniol, Julien and Bachellier, Philippe and Detour, Julien and Duclos, Bernard and Greget, Michel and Habersetzer, Francois and Imperiale, Alessio and Merle, Philippe and Rode, Agnès and Morvan, Julie and Nguyen-Khac, Eric and Yzet, Thierry and Baudin, Guillaume and Chevallier, Patrick and Mahamat, Abakar and Piche, Thierry and Razzouk, Micheline and Hillon, Patrick and Loffroy, Romaric and Toubeau, Michel and Vincent, Julie and Barabino, Gabriele and Bouarioua, Nadia and Cuilleron, Muriel and Ecochard, Marie and Prevot-Bitot, Nathalie and Leroy, Vincent and Roux, Julie and Sengel, Christian and Bourcier, Valérie and Ganne-Carrie, Nathalie and Seror, Olivier and Costo, Sylvie and Dao, Thông and Pelage, Jean-Pierre and Dumortier, Jérôme and Giammarile, Francesco and Valette, Pierre-Jean and Ghazzar, Nadia and Pellerin, Olivier and Taieb, Julien and ... and SARAH Trial Grp and SARAH Trial Group
The Lancet Oncology, ISSN 1470-2045, 12/2017, Volume 18, Issue 12, pp. 1624 - 1636
Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma. We aimed to compare the efficacy and safety of sorafenib to that of... 
SURVIVAL | THERAPY | ONCOLOGY | COMPETING RISK | TRANSARTERIAL CHEMOEMBOLIZATION | RADIOEMBOLIZATION | QUALITY-OF-LIFE | Niacinamide - analogs & derivatives | Carcinoma, Hepatocellular - mortality | Follow-Up Studies | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Liver Neoplasms - mortality | Dose-Response Relationship, Drug | Microspheres | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Neoplasm Invasiveness - pathology | Phenylurea Compounds - adverse effects | Adult | Female | Liver Neoplasms - pathology | Yttrium Radioisotopes - therapeutic use | Radiotherapy Dosage | Drug Administration Schedule | Administration, Oral | Brachytherapy - methods | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Niacinamide - adverse effects | Carcinoma, Hepatocellular - radiotherapy | Treatment Outcome | Niacinamide - administration & dosage | Disease-Free Survival | Phenylurea Compounds - administration & dosage | Liver Neoplasms - radiotherapy | Sorafenib | Carcinoma, Hepatocellular - pathology | Survival Analysis | Aged | Neoplasm Staging | Rare earth metals | Antimitotic agents | Product development | Hepatoma | Comparative analysis | Radiotherapy | Antineoplastic agents | Life Sciences | Liver Neoplasms/drug therapy | Phenylurea Compounds/administration & dosage | Yttrium Radioisotopes/therapeutic use | Niacinamide/analogs & derivatives | Carcinoma, Hepatocellular/radiotherapy | Carcinoma, Hepatocellular/drug therapy | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2018, Volume 379, Issue 25, pp. 2395 - 2406
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 819 - 828
Summary Background Gemcitabine plus a platinum-based agent (eg, cisplatin or oxaliplatin) is the standard of care for advanced biliary cancers. We investigated... 
Hematology, Oncology and Palliative Medicine | GROWTH-FACTOR RECEPTOR | MULTICENTER | CISPLATIN | ONCOLOGY | COLORECTAL-CANCER | CLINICAL-TRIALS | GALLBLADDER | COMBINATION | TUMORS | CHEMOTHERAPY | GALL-BLADDER CANCER | ras Proteins - genetics | Peripheral Nervous System Diseases - chemically induced | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Alanine Transaminase - blood | Organoplatinum Compounds - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Oxaliplatin | Common Bile Duct Neoplasms - drug therapy | Adult | Bile Ducts, Intrahepatic | Female | Bile Duct Neoplasms - genetics | Cetuximab | Neutropenia - chemically induced | Common Bile Duct Neoplasms - genetics | Bile Duct Neoplasms - drug therapy | Carcinoma - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Deoxycytidine - administration & dosage | Gallbladder Neoplasms - genetics | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Gallbladder Neoplasms - drug therapy | Aspartate Aminotransferases - blood | Cholangiocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Cholangiocarcinoma - genetics | Carcinoma - genetics | Aged | Mutation | Deoxycytidine - analogs & derivatives | Chemotherapy | Product development | Gemcitabine | Comparative analysis | Cancer
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2011, Volume 364, Issue 19, pp. 1817 - 1825
In this study, a four-drug combination chemotherapy regimen was associated with objective responses in more than 30% of patients and increased survival by more... 
PHASE-III TRIAL | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | SOLID TUMORS | CLINICAL-TRIALS | IRINOTECAN | OXALIPLATIN | 1ST-LINE THERAPY | COMBINATION | CARCINOMA | COOPERATIVE-ONCOLOGY-GROUP | Leucovorin - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Pancreatic Neoplasms - drug therapy | Deoxycytidine - therapeutic use | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Neoplasm Metastasis - drug therapy | Adult | Camptothecin - administration & dosage | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Camptothecin - analogs & derivatives | Severity of Illness Index | Pancreatic Neoplasms - pathology | Proportional Hazards Models | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Survival Analysis | Quality of Life | Aged | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Chemotherapy, Combination | Usage | Care and treatment | Gemcitabine | Pancreatic cancer | Leucovorin | Comparative analysis | Drug therapy | Fluorouracil | Clinical trials | Cytotoxicity | Pancreas | Patients | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2017, Volume 66, Issue 6, pp. 1166 - 1172
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2013, Volume 31, Issue 28, pp. 3509 - 3516
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 4_suppl, pp. 427 - 427
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2017, Volume 23, Issue 17, pp. 5267 - 5280
Purpose: Patients with metastatic colorectal cancer suffer from disease relapse mainly due to cancer stem cells (CSC). Interestingly, they have an increased... 
GASTRIN | ACTIVATION | INHIBITION | METASTASIS | ONCOGENIC RAS | ONCOLOGY | SIGNALING PATHWAY | GROWTH | RESISTANCE | THERAPIES | EXPRESSION | Protein Precursors - blood | Neoplastic Stem Cells - drug effects | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Humans | Neoplasm Recurrence, Local - drug therapy | Neoplasm Recurrence, Local - pathology | Protein Precursors - antagonists & inhibitors | Antibodies, Anti-Idiotypic - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Colorectal Neoplasms - drug therapy | Gene Expression Regulation, Neoplastic - drug effects | Gastrins - blood | Antibodies, Anti-Idiotypic - immunology | Gastrins - antagonists & inhibitors | Protein Precursors - immunology | Gastrins - immunology | HT29 Cells | Animals | Wnt Signaling Pathway - drug effects | Neoplasm Recurrence, Local - genetics | Cell Proliferation - drug effects | Mice | Mutation | Colorectal Neoplasms - pathology | Wnt protein | Colorectal carcinoma | Colorectal cancer | Medical services | Antibodies | Stem cell transplantation | Raf protein | Cancer therapies | K-Ras protein | Metastases | β-catenin | Allografts | Intestine | Colon | Immunoglobulins | Cell survival | Therapeutic applications | Transgenic mice | Tumor cell lines | Cell differentiation | Patients | Signaling | Chemotherapy | Lymphocytes B | Experimental design | Cell lines | Stem cells | Monoclonal antibodies | Cell migration | Tumors | Cancer | Life Sciences
Journal Article